Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.

BACKGROUND: Imatinib dose escalation is advocated for gastrointestinal stromal tumour (GIST) treatment, but its effectiveness compared with sunitinib and best supportive care (BSC) after failure at the 400 mg/day dose is unknown. OBJECTIVES: To assess the effectiveness and cost-effectiveness of imat...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Health Technol Assess
Päätekijät: Hislop, J, Quayyum, Z, Elders, A, Fraser, C, Jenkinson, D, Mowatt, G, Sharma, P, Vale, L, Petty, R
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: NIHR Journals Library 2011
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4781615/
https://ncbi.nlm.nih.gov/pubmed/21689502
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta15250
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia